Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium lactis Probio-M8 + budesonide + formoterol
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Inhalation
01
Overview
A combination therapy consisting of the probiotic strain Bifidobacterium lactis Probio-M8 with budesonide (a corticosteroid) and formoterol (a long-acting beta-agonist). Bifidobacterium lactis Probio-M8 is a probiotic strain isolated from human breast milk that has shown benefits in various conditions including respiratory tract infections, coronary artery disease, and modulation of immune responses. Budesonide is an anti-inflammatory corticosteroid, while formoterol is a long-acting beta-2 agonist bronchodilator. This specific combination may be intended to provide both respiratory symptom relief and probiotic benefits, though clinical studies on this exact combination are not evident in the available information.
02
Targets
ADRB2 (β2)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on Bifidobacterium lactis Probio-M8 + budesonide + formoterol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium lactis Probio-M8 + budesonide + formoterol.